Biotech 

Biotechnology is advancing faster than ever. With global biotech venture capital investment surpassing $5 billion in Q1 2026 alone, the sector is attracting record levels of attention from researchers, investors, and healthcare leaders. From gene editing and cell therapy to AI-driven drug discovery and next-generation biologics, the pace of innovation demands reliable, timely reporting.

Life Science Daily News covers the biotech stories that matter, including breakthrough medical research, CRISPR and base editing developments, antibody-drug conjugates, biosimilar approvals, and the deals reshaping the biopharmaceutical industry. Coverage spans early-stage drug development through to clinical trials, drug approvals, and commercial launch, giving you a complete view of the biotechnology pipeline.

Therapeutic areas include oncology, rare diseases, autoimmune disorders, neuroscience, cardiovascular disease, and infectious disease. The technologies driving healthcare innovation across these fields are also a core focus: genomics and precision medicine, CAR-T and cell therapy, radiopharmaceuticals, GLP-1 receptor agonists and obesity drug development, and artificial intelligence in drug discovery.

The commercial side of biotech matters just as much as the science. Venture capital funding, IPO activity, major acquisitions, strategic partnerships, and the biotech companies shaping market trends all feature in our reporting, grounded in clinical trial data, peer-reviewed research, FDA and EMA regulatory filings, and expert commentary.

Explore the latest biotech articles on this page. Bookmark this page, subscribe for updates, or visit our other category pages for deeper coverage of clinical trials, pharma, health tech, and regulatory developments.

Don’t wait for the media to pick up your story. Be the media.